

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A combination of (a) an ATP-competitive inhibitor of c-abl kinase activity ~~and (b)~~ with (b) two or more other antineoplastic agents for simultaneous, separate or sequential use wherein the ATP-competitive inhibitor of c-abl kinase activity (a) is N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof, and (b) the two or more antineoplastic agents are selected from the group consisting of Idarubicine, Fludarabine and ara-C which are independently of each other present in free form or as pharmaceutically acceptable salts.

Claims 2-9 (canceled)

Claim 10 (currently amended): A pharmaceutical composition comprising a combination of (a) an ATP-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents and optionally at least one pharmaceutically acceptable carrier for the delay of progression or treatment of a proliferative disease in a warm-blooded animal, especially a human, in need of such treatment, wherein component (a) is (N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof, and component (b) includes two or more of the compounds selected from the group consisting of Idarubicine, Fludarabine and ara-C which are independently of each other present in free form or as pharmaceutically acceptable salts.

Claims 11-13 (canceled)

Claim 14 (currently amended): A commercial package comprising (a) an ATP-competitive inhibitor of c-abl kinase activity and (b) two or more other antineoplastic agents, where the active compounds falling under (a) and/or (b) are independently of each other in free form or in the form of pharmaceutically acceptable salts, for simultaneous, chronically staggered or (less preferably) separate use in the delay of progression or treatment of a proliferative disease wherein the ATP-competitive inhibitor of c-abl kinase activity (a) is N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) the two or more antineoplastic agents are selected from the group consisting of Idarubicine, Fludarabine and ara-C.